四种方法诊断慢性乙型肝炎合并轻度肝脂肪变患者肝纤维化比较

doi:10.3969/j.issn.1672-5069.2016.06.007

摘要/Abstract

摘要： 目的比较血清学诊断模型APRI、FIB-4 和Forns指数及FibroScan检查评估合并轻度肝脂肪变的CHB患者肝纤维化的价值。方法在309例经肝活检病理学检查确诊的CHB患者中，194例无肝脂肪变，115例合并轻度肝脂肪变，同期行FibroScan检查，得到肝硬度值（LSM），收集实验室检查指标，根据公式计算出相应的APRI、FIB-4、Forns指数。以肝组织病理学表现为金标准，根据受试者工作曲线（ROC）评价4种方法诊断两组患者肝纤维化的效能。结果两组患者LSM、APRI、FIB-4、Forns指数差异均无统计学意义（P均＞0.05）；在未合并肝脂肪变组，LSM、APRI、FIB-4、Forns指数诊断CHB患者明显肝纤维化（≥F2）的ROC曲线下面积（AUROC）分别为0.77、0.69、0.72、0.69（P均<0.05），其相应的截断点分别为10.2、0.5、0.9、5.3；诊断肝硬化（≥F4）时，其AUROC分别为0.86、0.72、0.77、0.77（P均<0.05），其相应的截断点分别为11.8、0.6、1.3、5.1；在合并肝脂肪变组，它们诊断CHB患者≥F2肝纤维化的AUROC分别为0.79、0.67、0.74、0.77（P均<0.05），其相应的截断点分别为9.7、0.4、1.1、5.7；诊断≥F4的AUROC分别为0.88、0.71、0.75、0.78（P均<0.05），其相应的截断点分别为11.8、1.1、1.5、5.4； APRI 和FIB-4不能诊断两组患者轻度肝纤维化（P＞0.05）；LSM诊断两组≥F2肝纤维化及≥F3或≥F4进展性肝纤维化或肝硬化的效能均优于APRI。结论 APRI评价合并轻度肝脂肪变的CHB患者肝纤维化效能较差，而LSM、FIB-4、Forns指数诊断效能较好，其中轻度肝脂肪变可能影响Forns指数诊断CHB患者肝纤维化效能。

关键词: 慢性乙型肝炎, 肝脂肪变, 肝纤维化, 诊断

Abstract: Objective To compare the efficacy of serological diagnosis model （APRI，FIB-4，Forns index） and Transient elastography （FibroScan） in evaluation of liver fibrosis in chronic hepatitis B （CHB） patients with mild hepatic steatosis. Methods Three hundred and nine patients with CHB proven by liver biopsy were recruited in this study. Out of them，194 had no，and 115 had hepatic steatosis. All patients with CHB were checked-up by FibroScan to get the liver stiffness measurement （LSM），and we collected the laboratory indexes to calculate the APRI，FIB-4 and Forns index. We evaluated the efficacies of the four Methods in diagnosis of liver fibrosis based on liver biopsy as the gold standard. Results The differences of LSM，APRI，FIB-4，Forns index in patients with and without liver steatosis were not statistically significant（all P>0.05）；The area under the ROC curve （AUROC） of LSM，APRI，FIB-4 and Forns index for the diagnosis of obvious liver fibrosis （≥F2） in CHB patients without hepatic steatosis were 0.77，0.69，0.72 and 0.69 （all P<0.05），and its corresponding cut-off-values were 10.2，0.5，0.9 and 5.3；the AUROC for the diagnosis of liver cirrhosis（≥F4） were 0.86，0.72，0.77 and 0.77（all P<0.05），and its corresponding cut-off-value were 11.8，0.6，1.3 and 5.1；The AUROC of LSM，APRI，FIB-4 and Forns index for the diagnosis of obvious liver fibrosis （≥F2） in CHB patients with mild hepatic steatosis were 0.79，0.67，0.74 and 0.77 （all P<0.05） and its corresponding cut-off-valures were 9.7，0.4，1.1 and 5.4；the AUROC for the diagnosis of liver cirrhosis（≥F4） were 0.88，0.71, 0.75 and 0.78（all P<0.05），and its corresponding cut-off-values were 11.8，1.1，1.5 and 5.4；The APRI and FIB-4 didn’t find light hepatic fibrosis in the two groups（P＞0.05；The efficacy of LSM for the diagnosis of hepatic fibrosis was superior to APRI. Conclusions The APRI assessment for the liver fibrosis in patients with CHB with mild liver steatosis is poor，while the LSM，FIB-4 and Forns index are good. The mild hepatic steatosis might affect the diagnosis of Forns index in CHB patients with liver fibrosis.

Key words: Hepatitis B, Hepatic steatosis, Hepatic fibrosis, Diagnosis

张舰琼，徐亮，李萍，刘勇钢，石瑞芳，宓余强. 四种方法诊断慢性乙型肝炎合并轻度肝脂肪变患者肝纤维化比较[J]. 实用肝脏病杂志, 2016, 19(6): 663-668.

Zhang Jianqiong，Xu Liang，Li Ping，et al.. Diagnostic efficacy of FibroScan and three diagnostic models in diagnosis of liver fibrosis in chronic hepatitis B patients with mild hepatic steatosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 663-668.

参考文献

[1] World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection.（2015.03）.http://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/.
[2] Minakari M，Molaei M，Shalmani HM，et al.Liver steatosis in patients with chronic hepatitis B infection:host and viral risk factors. Eur J Gastroenterol Hepatol，2009，21（5）:512-516.
[3] 宓余强，刘勇钢，徐亮，等.慢性乙型肝炎合并肝脂肪变的临床与病理学特征分析. 中华肝脏病杂志，2009，17（11）:817-819.
[4] Obara N，Ueno Y，Fukushima K，et al.Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases. J Gastroenterol，2008，43（9）:720-728.
[5] Shin WG，Park SH，Jang MK，et al. Aspartate aminotransferase to platelet ratio index（APRI） can predict liver fibrosis in chronic hepatitis B.Dig Liver Dis，2008，40（4）:267-274.
[6] Basar O，Yimaz B，Ekiz F，et al. Non-invasive tests in prediction of liver fibrosis in chronic hepatitis B andcomparison with post-antiviral treatment results. Clin Res Hepatol Gastroenterol，2013，37（2）:152-158.
[7] 中华医学会肝病学分会，中华医学会感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志，2011，14（2）:81-89.
[8] Wai CT，Greenson JK，Fontana RJ，et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology，2003，38（2）:518-526.
[9] Sterling RK，Lissen E，Clumeck N，et al. Development of a simple noninvasive index to predict significant fibrosisin patients with HIV/HCV coinfection.Hepatology，2006，43（6）:1317-1325.
[10] Forns X，Ampurdanes S，Llovet JM，et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model.Hepatology，2002，36（4）:986-992.
[11] Bedossa P，Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology，1996，24（2）:289-293.
[12] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南（2010年修订版）. 中华肝脏病杂志，2010，18（3）:163-166.
[13] Peng DD，Han Y，Ding HG，et al. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors.J Gastroenterol Hepatol，2008，23（7 Pt 1）:1082-1088.
[14] Shi JP，Fan JG，Wu R，et al. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol，2008，23（9）:1419-1425.
[15] Petta S，Camma C，Marco VD，et al. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. Liver Int，2011，31（4）:507-515.
[16] Zheng RD，Xu CR，Jiang L，et al. Predictors of hepatic steatosis in HBeAg-negative chronic hepatitis B patients and their diagnostic values in hepatic fibrosis. Int J Med Sci，2010，7（5）:272-277.
[17] 刘淑娥，郝美娜，任亚楠，等. 慢性乙型肝炎患者合并脂肪肝导致单纯抗病毒治疗生物化学应答不佳诊疗分析. 中华肝脏病杂志，2015，23（5）:333-338.
[18] Cheng YL，Wang YJ，Kao Y，et al. Inverse association between hepatitis B virus infection and fatty liver disease:a large-scale study in populations seeking for check-up. PLoS One，2013，8（8）:e72049.
[19] 邹志强，王均蒙，王莉，等. 慢性乙型肝炎合并脂肪变对Fibroscan检测肝脏硬度值的影响. 中华实验和临床病毒学杂志，2014，28（2）:96-98.
[20] Gaia S，Carenzi S，Barilli AL，et al. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol，2011，54（1）:64-71.
[21] Cheng J，Hou J，Ding H，et al.Validation of ten noninvasive diagnostic models for prediction of liver fibrosis in patients with chronic hepatitis B.PLoS One，10（12）:e0144425.
[22] Lauren L，Alain D，Karine B，et al.Automatic detection of cirrhosis in hospitalized patients:a pragmatic experience. Eur J Gastroenterol Hepatol，2016，28（1）:74–81.
[23] Mi YQ，Shi QY，Xu L，et al. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan: validation in chronic hepatitis B.Dig Dis Sci，2015，60（1）:243-251.
[24] Li Y，Cai Q，Zhang Y，et al. Development of algorithms based on serum markers and Fibroscan for detecting significant fibrosis and cirrhosis in chronic hepatitis B patients:Significant reduction in liver biopsy. Hepatol Res，2016，Mar11.doi:10.1111/hepr.12696.